PCN95 COST-EFFECTIVENESS OF SEROTONIN-TYPE 3 RECEPTOR ANTAGONISTS FOR CHEMOTHERAPY-INDUCED EMESIS IN NON SMALL CELL LUNG CANCER PATIENTS RECEIVING CISPLATIN-BASED CHEMOTHERAPY
May 1, 2010, 00:00
10.1016/S1098-3015(10)72184-7
https://www.valueinhealthjournal.com/article/S1098-3015(10)72184-7/fulltext
Title :
PCN95 COST-EFFECTIVENESS OF SEROTONIN-TYPE 3 RECEPTOR ANTAGONISTS FOR CHEMOTHERAPY-INDUCED EMESIS IN NON SMALL CELL LUNG CANCER PATIENTS RECEIVING CISPLATIN-BASED CHEMOTHERAPY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)72184-7&doi=10.1016/S1098-3015(10)72184-7
First page :
Section Title :
Open access? :
No
Section Order :
771